Surgically treated pneumonic-type lung adenocarcinoma with long survival characteristics

Year 2023, , 345 - 349, 27.10.2023

Derya Kızılgöz , Pınar Akın Kabalak , Suna Kavurgacı , Tuba İnal Cengiz , Funda Demirağ , Leyla Nesrin Acar , Şebnem Yücel , Özlem Özmen , Ülkü Yılmaz

https://doi.org/10.38053/acmj.1340516

Abstract

Aims: Pneumonic-type lung adenocarcinoma is defined as a pneumonia-like area of infiltration or consolidation involving a region of the lung. These carcinomas, which are suitable for curative treatment options and have a long survival when detected at an early stage, may resemble infectious or inflammatory lung diseases due to their radiological appearance and clinical findings, may lead to potential delays or difficulties in diagnosis, and this may cause progression in patients who are suitable for curative treatment options.
Methods: A total of 41 patients which were surgically treated between 2011-2020 and diagnosed pathologically with pneumonic-type adenocarcinoma. The patents’ TTF-1, type of operation, pathological stages, overall/progression-free survival, as well as overall/progression-free survival according to the type of operation and radiological appearance, were also evaluated.
Results: The study included 41 patients. Although overall survival times were long, there was no statistically significant defference between wedge resection and lobectomy group in overall survival by operation type. Although progression-free survival times were long, there was no statistically significant defference between wedge resection and lobectomy group in progression-free survival by operation type. There was no statistically significant difference between solid and consolidated groups in terms of overall survival and progression-free survival according to radiological appearances. There was no statistically significant difference between TTF-1 positive and negative groups in overall survival.
Conclusion: Pneumonic-type lung adenocarcinomas respond to curative treatments when diagnosed at an early stage. The optimal treatment method for operable patients is surgery, which is associated with prolonged survival.

Keywords

Lung cancer, pneumonic-type adenocarcinoma, surgical treatment

References

• Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11 (5):666–680.
• Saitoa S,Espinoza-Mercadob F,Liu H, et al. Current status of research and treatment for non-small cell lung cancer in never smoker females. Cancer Biol Ther. 2017;18(6):359–368. doi: 10.1080/15384047.2017.1323580
• Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015;10(9):1240-1242.
• Beck KS,Sung YE,Lee KY,Han DH. Invasive mucinous adenocarcinoma of the lung: serial CT findings, clinical features, and treatment and survival outcomes. Thorac Cancer. 2020;11(12):3463-3472. doi: 10.1111/1759-7714.13674
• Zhang S,Yu X,Huang Y, et al. Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers. BMC Pulm Med. 2022;22(1):460. doi: 10.1186/s12890-022-02268-5
• Wislez M, Massiani M-A, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest. 2003;123:1868-1877.
• Li Q, Fan X, Huo JW, Luo TY, Huang XT, Gong JW. Differential diagnosis of localized pneumonic-type lung adenocarcinoma and pulmonary inflammatory lesion. Insights Imaging. 2022;13(1):49. doi: 10.1186/s13244-022-01200-z
• Barlesi F, Doddoli C, Gimenez C, et al. Bronchioloalveolar carcinoma: myths and realities in the surgical management. Eur J Cardiothorac Surg. 2003;24:159-164.
• Ishibashi H, Niikawa H, Ishida I, et al. Primary lung cancer incidentally diagnosed in lung biopsy for diffuse pulmonary disease. Kyobu Geka. 2005;58:813–817.
• Huo JW, Huang XT, Li X, Gong JW, Luo TY, Li Q. Pneumonic-type lung adenocarcinoma with different ranges exhibiting different clinical, imaging, and pathological characteristics. Insights Imaging. 2021;12:169. doi: 10.1186/s13244-021-01114-2
• Yoshino R, Yoshida N, Ito A, Ujiie N, Nakatsubo M, Kitada M. Surgical resection of a large invasive mucinous adenocarcinoma:A case report. Clin Case Rep. 2023;11(7):e7707. doi: 10.1002/ccr3.7707
• Wei J, Tang D, Nie Y, Chen J, Peng L. Clinical characteristics and prognosis of nonsurgically treated patients with pneumonic-type adenocarcinoma. Medicine (Baltimore). 2019;98(18):e15420.doi: 10.1097/MD.0000000000015420
• Kim W, Lee SM, Lee JB, et al. Prognosis for pneumonic-type invasive mucinous adenocarcinoma in a single lobe on CT: is it reasonable to designate it as clinical T3? Korean J Radiol. 2022;23(3):370-380. doi: 10.3348/kjr.2021.0465
• Wislez M, Massiani M-A, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest. 2003;123:1868-1877.
• Yongjian Liu , Ji Li , Shibo Wang , et al. Advanced pneumonic-type lung carcinoma: a retrospective study of clinical-radiological-pathological characteristics with survival analysis in a single Chinese hospital. Zhongguo Fei Ai Za Zhi. 2019;22(6):329-335.
• Régnard JF, Santelmo N, Romdhani N, et al. Bronchioloalveolar lung carcinoma: results of surgical treatment and prognostic factors. Chest. 1998;114:45-50.
• Okubo K, Mark EJ, Flieder D, et al. Bronchoalveolar carcinoma: clinical, radiological, pathological factors and survival. J Thorac Cardiovasc Surg. 1999;118:702-709.
• Nie K, Nie W, Zhang YX, Yu H. Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings.Cancer Imaging. 2019;19(1):47.
• Wang T,Yang Y,Liu X, et al. Primary invasive mucinous adenocarcinoma of the lung: prognostic value of CT imaging features combined with clinical factors. Korean J Radiol. 2021;22(4):652-662. doi: 10.3348/kjr.2020.0454.
• Zhang Y, Wang R, Li Y, et al. Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas. J Thorac Oncol. 2015;10:1444-1150.